Randox Promotes Evidence MultiSTAT Automated Benchtop Immunoassay Analyzer
|
By Theresa Herman, Regional Director Posted on 31 Jan 2019 |

Image: The Evidence MultiSTAT analyzer (Photo courtesy of Randox Laboratories).
Randox Laboratories (Crumlin, UK) participated in MedLab Middle East 2019 held in Dubai, UAE, from February 4-7, 2019, where it offered live product demonstrations of the Evidence MultiSTAT automated benchtop immunoassay analyzer.
The Evidence MultiSTAT simultaneously detects up to 21 classical, prescription and synthetic drugs from a single patient sample. Utilizing revolutionary Biochip Array Technology, it uses a chemiluminescence reaction as a measuring principle to ensure consistently accurate results. Moving away from traditional single analyte assays, Biochip Array Technology boasts of cutting-edge multiplex testing capabilities providing rapid and accurate drug detection from a single sample. Biochip Array Technology has a proven high standard of accurate test results with CVs typically <10% with a 98% agreement with confirmatory methods.
Based on ELISA principles, the biochip is a solid-state device with discrete test sites onto which antibodies specific to different drug compounds are immobilized and stabilized. Competitive chemiluminescent immunoassays are then employed, offering a highly sensitive screen. Testing panels are available for blood and urine samples to accommodate various testing requirements, with a minimal 200ul sample volume required, ensuring more sample is available for confirmatory testing.
Randox has the world’s largest toxicology test menu, with the ability to detect over 500 drugs and drug metabolites. Randox also has the world’s most advanced drug screening test menu spanning a wide range of classical, prescription and synthetic drugs of abuse. The Evidence Multistat provides a complete drug profile in one simple process, reducing the amount of time and labor spent on individual tests. The reliability and accuracy of results also reduces the financial burden of re-testing. With multiple results obtained in less than 20 minutes, the Evidence MultiSTAT is an ideal analyzer for emergency drugs of abuse screening.
The Evidence MultiSTAT simultaneously detects up to 21 classical, prescription and synthetic drugs from a single patient sample. Utilizing revolutionary Biochip Array Technology, it uses a chemiluminescence reaction as a measuring principle to ensure consistently accurate results. Moving away from traditional single analyte assays, Biochip Array Technology boasts of cutting-edge multiplex testing capabilities providing rapid and accurate drug detection from a single sample. Biochip Array Technology has a proven high standard of accurate test results with CVs typically <10% with a 98% agreement with confirmatory methods.
Based on ELISA principles, the biochip is a solid-state device with discrete test sites onto which antibodies specific to different drug compounds are immobilized and stabilized. Competitive chemiluminescent immunoassays are then employed, offering a highly sensitive screen. Testing panels are available for blood and urine samples to accommodate various testing requirements, with a minimal 200ul sample volume required, ensuring more sample is available for confirmatory testing.
Randox has the world’s largest toxicology test menu, with the ability to detect over 500 drugs and drug metabolites. Randox also has the world’s most advanced drug screening test menu spanning a wide range of classical, prescription and synthetic drugs of abuse. The Evidence Multistat provides a complete drug profile in one simple process, reducing the amount of time and labor spent on individual tests. The reliability and accuracy of results also reduces the financial burden of re-testing. With multiple results obtained in less than 20 minutes, the Evidence MultiSTAT is an ideal analyzer for emergency drugs of abuse screening.
Latest MEDLAB 2019 News
- ERBA Group Launches New Hematology Analyzers at MEDLAB 2019
- Telstar Promotes Latest Generation of Freeze Dryers in Dubai
- Siemens Healthineers Showcases In-Vitro Diagnostics Products at MedLab 2019
- Mindray Displays New Generation Benchtop Cellular Analysis Line
- HORIBA Medical Shows Latest Yumizen G Range at Lab Trade Show
- Greiner Bio-One Displays Range of Safety Products at MedLab
- EKF Diagnostics Presents Latest Diabetes Care Analyzers
- BioSystems Highlights New iFOB Integral System at MedLab 2019
- Beckman Coulter Exhibits New Hematology Analyzer in Middle East
- Agappe Diagnostics Displays Analyzers and Solutions at Middle East Congress
- Abbott Highlights Point of Care Management Solutions
Channels
Clinical Chemistry
view channel
FDA-Approved Test Identifies Low Risk of Large Esophageal Varices in Cirrhosis
Chronic liver disease contributes substantially to mortality, and clinicians routinely screen adults with compensated cirrhosis for varices to prevent bleeding. However, endoscopy is invasive and reso... Read more
Blood Protein Signature Diagnoses Pediatric IBD and Distinguishes Subtypes
Confirming pediatric inflammatory bowel disease (IBD) often requires imaging, endoscopy, and histopathology, prolonging time to diagnosis. Reliable, noninvasive blood tests remain an unmet need in routine... Read moreMolecular Diagnostics
view channel
Ultrasensitive ctDNA Assay Detects MRD in Breast, Colorectal, Renal Cancers
Minimal residual disease testing is increasingly used to guide adjuvant therapy and surveillance in solid tumors, but detecting very low levels of circulating tumor DNA remains challenging in routine practice.... Read more
Female-Specific RNA Biomarker May Help Explain Sex Differences in Immune Disease
Women show distinct susceptibility to infectious diseases and higher rates of autoimmune disorders, yet the molecular drivers remain unclear. This gap has limited sex-specific diagnostic and prognostic tools.... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
New Cellular Biomarkers Correlate with Disease Severity in Sjögren Disease
Autoimmune disorders arise when immune responses target self-antigens, driving chronic inflammation and long-term morbidity. In primary Sjögren disease, inflammation of salivary and lacrimal glands leads... Read more
Airway Immune Signature May Predict Tuberculosis Progression Risk
Tuberculosis remains difficult to predict and prevent, despite widespread exposure worldwide. An estimated quarter of the global population has been infected with Mycobacterium tuberculosis, yet only a... Read moreMicrobiology
view channel
Machine Learning Reveals Consistent Gut Microbiome Patterns in Colorectal Cancer
Colorectal cancer has been repeatedly linked to alterations in the gut microbiome, yet findings have often varied across small, heterogeneous studies. Reproducibility has been limited by differing sequencing... Read more
Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella
Multidrug-resistant Klebsiella pneumoniae is an escalating community health concern, driving recurrent urinary tract infections in older adults and complicating first-line antibiotic therapy.... Read more
Stronger Laboratory Services Support Timely Melioidosis Diagnosis Amid Global Spread
Melioidosis, a potentially fatal infection caused by Burkholderia pseudomallei, remains difficult to recognize because its symptoms can mimic tuberculosis and other illnesses. The disease is considered... Read more
Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori
Helicobacter pylori infects an estimated 43.9% of the global population, affecting approximately 4.4 billion people worldwide. In many regions, including Africa, Eastern Europe, and Southeast Asia, prevalence... Read morePathology
view channel
Uncertainty-Aware AI Tool Improves Digital Pathology for Cancer Subtyping
Reliable histologic subtyping guides therapy selection in oncology, yet diagnostic workflows grow more complex as whole-slide imaging and artificial intelligence (AI) expand. A persistent obstacle to clinical... Read more
Study Highlights Biomarker Testing Delays in Lung Cancer Care
Timely biomarker results are critical to match lung cancer patients with targeted therapies or immunotherapies, yet many clinical pathways still delay testing after biopsy. Ordering responsibility, reimbursement... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Project Aims to Develop First Single-Cell Assay for ADC Therapies
Antibody-drug conjugates are expanding rapidly in oncology, intensifying the need for biomarker strategies that capture tumor heterogeneity at cellular resolution. Single-cell profiling can delineate cellular... Read more









